Humacyte

HUMA · NASDAQ

$0.406+$0.0049 (+1.22%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $0.4011

HUMA analyst rating

BuyConsensus of 8 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy6
Hold2
Underperform0
Sell0

12-month price target · 7 analysts

Average $1.89 (+364.8% upside)

Low: $1.01
Now: $0.406
High: $4.20

Upgrades and downgrades

The latest rating actions, newest first

HUMA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Oct 7, 2026	Initiates	Equal-Weight	$0.50	68%
Benchmark	Aug 13, 2026	Maintains	Speculative Buy	$2.00 → $1.00	59%
BTIG	Jul 28, 2026	Maintains	Buy	$2.00	48%
TD Cowen	Jun 17, 2026	Maintains	Buy	$1.50 → $1.25	48%
BTIG	Jun 16, 2026	Maintains	Buy	$2.00	48%
HC Wainwright & Co.	Jun 11, 2026	Maintains	Buy	$3.00 → $4.00	43%
BTIG	Jun 8, 2026	Maintains	Buy	$2.00	48%
Benchmark	Jun 1, 2026	Maintains	Speculative Buy	$1.00 → $2.00	59%
HC Wainwright & Co.	May 26, 2026	Maintains	Buy	$3.00	43%
TD Cowen	May 14, 2026	Maintains	Buy	$1.00 → $1.50	48%

The case for and against

Updated Oct 14, 2026

Bull case

Humacyte is positioned favorably because its ATEV platform has already shown strong clinical validation, including the V012 interim result of 220 catheter-free days versus 129 for standard AV fistula care with statistical significance (p=0.00070), plus lower infections and no study-access-associated infections. The dialysis-access opportunity materially expands the addressable market, with nearly 500,000 Americans on hemodialysis, roughly $3B in annual Medicare access-related complication spending, and a planned sBLA in 2H26 that could support a 2027 launch. Its outlook is further strengthened by existing commercial approval for Symvess, manufacturing scale, and a partnership with Fresenius Medical Care that can accelerate adoption while the company also raised $50M in gross proceeds, reducing near-term financing pressure.

Bear case

Humacyte is burdened by weak near-term commercial execution, with 2Q revenue of just $0.4 million versus $1.1 million consensus and a $1.2 million estimate, suggesting demand remains far below expectations despite commercial-stage status. The company’s sales force overhaul and added medical-education spending may help later, but management still lowered 2026 revenue to $4.9 million from $6.6 million, underscoring uncertain adoption for vascular grafts and hemodialysis access. It also remains loss-making and may need additional capital, while clinical, regulatory, manufacturing comparability, and intellectual-property risks could delay approval, raise dilution risk, and keep profitability several years away.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.